@article{article, title  = {{694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2020}},

 month = {{9}},

 author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin A and Bracken K and Roncolato F and McJannett M and Horvath L and Sengupta S and Hughes S et al}},

 doi = {{10.1016/j.annonc.2020.08.2088}},

 volume = {{31}},

 journal = {{Annals of Oncology}},

 pages = {{S548-S549}},

 note = {{Accessed on 2024/12/22}}}